

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.org) on Apr 11, 2025

## COST

RRID:SCR\_014098

Type: Tool

---

### Proper Citation

COST (RRID:SCR\_014098)

---

### Resource Information

**URL:** [http://www.nitrc.org/projects/cost\\_unc/](http://www.nitrc.org/projects/cost_unc/)

**Proper Citation:** COST (RRID:SCR\_014098)

**Description:** A tool that implements a graph-based connectivity assessment method. This method uses a multi-directional graph propagation method applied to sampled orientation distribution function (ODF), which can be computed directly from the original diffusion imaging data.

**Abbreviations:** COST

**Synonyms:** Connectivity Orientation Spherical distribution Tool

**Resource Type:** software resource, software application, data processing software, image analysis software

**Keywords:** software tool, connectivity assessment, image analysis software

**Funding:**

**Resource Name:** COST

**Resource ID:** SCR\_014098

**Record Creation Time:** 20220129T080319+0000

**Record Last Update:** 20250411T055645+0000

---

### Ratings and Alerts

No rating or validation information has been found for COST.

No alerts have been found for COST.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 3920 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Kang DW, et al. (2025) Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA. *PharmacoEconomics - open*, 9(1), 93.

Paulissen JHJ, et al. (2025) Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy. *Advances in therapy*, 42(1), 322.

Rink JS, et al. (2025) Mobile stroke units services in Germany: A cost-effectiveness modeling perspective on catchment zones, operating modes, and staffing. *European journal of neurology*, 32(1), e16514.

Kongmalai T, et al. (2025) Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand. *PharmacoEconomics - open*, 9(1), 69.

Atreja N, et al. (2025) US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total. *Journal of comparative effectiveness research*, 14(1), e240163.

Settumba S, et al. (2025) Provider costs of treating opioid dependence with extended-release buprenorphine in Australia. *Drug and alcohol review*, 44(1), 179.

Guarducci S, et al. (2025) Key Fundamentals and Examples of Sensors for Human Health: Wearable, Non-Continuous, and Non-Contact Monitoring Devices. *Sensors (Basel, Switzerland)*, 25(2).

Wang D, et al. (2025) Ir-O-Mn embedded in porous nanosheets enhances charge transfer in low-iridium PEM electrolyzers. *Nature communications*, 16(1), 181.

Shinohara A, et al. (2025) Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data. *Scientific reports*,

15(1), 267.

Han L, et al. (2025) Study on the spatial and temporal evolution of ecosystem service value based on land use change in Xi'an City. *Scientific reports*, 15(1), 66.

Okeahialam N, et al. (2025) Effects of strategies to tackle racism experienced by healthcare professionals: a systematic review. *BMJ open*, 15(1), e091811.

Lefèvre G, et al. (2025) Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. *PloS one*, 20(1), e0313694.

Wagner GJ, et al. (2025) Study protocol for a hybrid implementation-effectiveness trial of Game Changers for Cervical Cancer Prevention in Uganda. *PloS one*, 20(1), e0317491.

Li J, et al. (2025) Cost-utility analysis of provision of e-cigarette starter kits for smoking cessation in emergency departments: An economic evaluation of a randomized controlled trial. *Addiction (Abingdon, England)*, 120(2), 368.

Fischer A, et al. (2025) Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study. *PharmacoEconomics - open*, 9(1), 41.

Piero Antonio Z, et al. (2025) DIY adapting SEM for low-voltage TEM imaging. *Microscopy research and technique*, 88(1), 17.

Lerner DK, et al. (2025) Time is money: An analysis of cost drivers in ambulatory sinus surgery. *International forum of allergy & rhinology*, 15(2), 120.

Chu MM, et al. (2025) A cost utility analysis for the management of acute exacerbations of chronic rhinosinusitis. *International forum of allergy & rhinology*, 15(2), 109.

Trostian B, et al. (2025) What proportion of women presenting to the emergency department with early pregnancy bleeding receive appropriate care? *Emergency medicine Australasia : EMA*, 37(1), e14507.

Mac Giolla Phadraig C, et al. (2025) Are orofacial pain assessment tools for adults who cannot self-report pain suitable for dental practice? A scoping review. *Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry*, 45(1), e13089.